Mar 15, 2021 4:05pm EDT Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Mar 04, 2021 8:00am EST Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference
Mar 01, 2021 4:05pm EST Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15
Feb 03, 2021 8:29am EST Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
Jan 20, 2021 8:13am EST ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES
Jan 05, 2021 8:00am EST ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT
Jan 04, 2021 7:00am EST ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
Dec 28, 2020 8:00am EST ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES
Dec 15, 2020 8:00am EST Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment
